Abstract:Rui Huang, 1, &ast Li Yan, 2, &ast Yuhua Lei 1 1 Cardiovascular Disease Center, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi Prefecture, 445000, Hubei Province, People's Republic of China; 2 Pediatrics Department, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi Prefecture, 445000, Hubei Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yuhua Lei No. 158 Wuyang Avenue, Enshi Prefecture, Hubei Province, People's Republic of China Email Accumulating evidence has demonstrated that gut microbial-derived metabolite trimethylamine N-oxide (TMAO) plays a crucial role in the pathogenesis of many diseases and can be served as a prognostic biomarker for several cardiovascular disorders, including arrhythmia. Recently, some studies have documented that TMAO was associated with the occurrence, progression, recurrence, and embolism risk of atrial fibrillation (AF). The activation of related inflammatory signal pathways and the cardiac sympathetic nervous system (CSNS) caused by elevated TAMO may be the underlying mechanism. It is worth noting that intervention in the metabolic pathway of TMAO may be an underlying therapeutic target of AF. In addition, standardized and individualized treatment strategies in clinical practice may be of great significance for AF patients, particularly those with high serum TMAO concentrations. However, there are also contradictions in the current research on TMAO and AF. Moreover, notwithstanding the positive preclinical and clinical findings, data supporting a direct association between TMAO and AF is a paucity. Thus, conclusive evidence from preclinical studies and multi-center randomized controlled trials to reveal the essential relationship between TMAO and AF is needy. In this review, we have attempted to summarize recent studies on TMAO and AF, highlighted the potential therapeutic strategies for AF patients, followed by a discussion on directions for future research in this field. Keywords: trimethylamine N-oxide, TMAO, atrial fibrillation Growing evidence indicated that gut microbiota-associated mechanisms play a pivotal role in the pathogenesis of many different complex human diseases. 1–4 The most well-studied agent exhibiting direct effects on arrhythmogenesis and other disorders is trimethylamine N-oxide (TMAO). This gut microbial-derived metabolite is derived from dietary choline or L-carnitine through gut microbiota, transforming choline to trimethylamine (TMA), a gas absorbed into the circulation and further converted into TMAO by flavin-containing monooxygenases (FMOs) in the liver. 2,5 Previous studies reported that TMAO was related to many human diseases, including cerebrovascular diseases, 6 renal insufficiency, 7 and cardiovascular diseases 2,4,8 such as hypertension, 9 coronary heart disease, 8,10 and heart failure. 11 The metabolic pathway of TMAO and its adverse effects are shown in Figure 1. TMAO may also be associated with cardiovascular events and mortality, which has also been confirmed in a recent meta-analysis 12 and hemodialysis sufferings. 13 Figure 1 The metabolic pathway of TMAO and its adverse effects on the body. Created by ScienceSlides Software and Microsoft Office PowerPoint Software. High-cholinergic foods are metabolized by intestinal microbes to form TMA, most of which enter the portal system through the blood circulation and are transferred into TMAO by the FMOs in the liver. Elevated TMAO has adverse impacts on various diseases. Abbreviations : TMA, trimethylamine; FMOs, flavin-containing monooxygenases; TMAO+, elevated TMAO. In addition, recent studies have begun to focus on the substantial role and pathogenetic mechanisms of intestinal microbiota and its metabolites, especially TMAO, in the field of arrhythmia and AF. 14,15 Despite the positive preclinical and clinical findings, few data supported a direct link between TMAO and AF with conflicting findings. Here, we reviewed the latest research on TMAO-AF and discussed the value of TMAO as a potential therapeutic target for patients with AF. It is noteworthy that the intestinal microbiota is a dynamic ecosystem composed of symbiotic and pathogenic microorganisms, affecting the health of the host through the production of bioactive metabolites. 15–18 TMAO is currently the most commonly studied intestinal microbial metabolite involved in human diseases. Surprisingly, at present, more and more studies have found that TMAO is inextricably linked to hypertension,< -Abstract Truncated-

The Gut Microbial-Derived Metabolite Trimethylamine N-Oxide and Atrial Fibrillation: Relationships, Mechanisms, and Therapeutic Strategies

Dysbiosis of Gut Microbiota With Reduced Trimethylamine-N-Oxide Level in Patients With Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack.

Dynamic Changes and Prognostic Value of Gut Microbiota-Dependent Trimethylamine-N-Oxide in Acute Ischemic Stroke.

Trimethylamine N-oxide: A New Therapeutic Target for Atrial Fibrillation?

Metagenomic data-mining reveals enrichment of trimethylamine-N-oxide synthesis in gut microbiome in atrial fibrillation patients

Gut Microbial Metabolite Trimethylamine N-Oxide Is Related to Thrombus Formation in Atrial Fibrillation Patients.

Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target

Gut microbiota-derived metabolites in atrial fibrillation: risk markers or modifiable risk factors?

A Potential Relationship Between Gut Microbes and Atrial Fibrillation: Trimethylamine N-oxide, a Gut Microbe-Derived Metabolite, Facilitates the Progression of Atrial Fibrillation.

The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases

Trimethylamine oxide: a potential target for heart failure therapy

Trimethylamine/Trimethylamine-N-Oxide as a Key Between Diet and Cardiovascular Diseases

Increased Plasma Trimethylamine- N -Oxide is Associated with Incident Atrial Fibrillation

Gut Microbe-Generated Metabolite Trimethylamine-N-Oxide and Ischemic Stroke

HIGHER CIRCULATING GUT MICROBIOTA-DEPENDENT METABOLITE TRIMETHYLAMINE N-OXIDE PLAYS AN ADVERSE EFFECT ON PULMONARY HYPERTENSION

Trimethylamine N-oxide: heart of the microbiota-CVD nexus?

Trimethylamine N-Oxide Levels Are Associated with Severe Aortic Stenosis and Predict Long-Term Adverse Outcome

Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD

Gut Microbial Metabolite Trimethylamine N-Oxide Aggravates Pulmonary Hypertension.

Gut microbiota-derived trimethylamine-N-oxide: A bridge between dietary fatty acid and cardiovascular disease?

Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy